EyePoint Pharmaceuticals Inc [EYPT] stock is trading at $8.72, up 14.29%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The EYPT shares have gain 21.11% over the last week, with a monthly amount glided 17.20%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
EyePoint Pharmaceuticals Inc [NASDAQ: EYPT] stock has seen the most recent analyst activity on January 07, 2025, when Citigroup initiated its Buy rating and assigned the stock a price target of $33. On August 28, 2024, Jefferies initiated with a Buy rating and assigned a price target of $15 on the stock. JP Morgan started tracking the stock assigning a Overweight rating and suggested a price target of $35 on January 22, 2024. Mizuho initiated its recommendation with a Buy and recommended $20 as its price target on November 02, 2023. Robert W. Baird started tracking with a Outperform rating for this stock on April 21, 2023, and assigned it a price target of $33. In a note dated July 07, 2022, Chardan Capital Markets initiated an Buy rating and provided a target price of $21 on this stock.
EyePoint Pharmaceuticals Inc [EYPT] stock has fluctuated between $6.90 and $30.99 over the past year. Currently, Wall Street analysts expect the stock to reach $22 within the next 12 months. EyePoint Pharmaceuticals Inc [NASDAQ: EYPT] shares were valued at $8.72 at the most recent close of the market. An investor can expect a potential return of 152.29% based on the average EYPT price forecast.
Analyzing the EYPT fundamentals
EyePoint Pharmaceuticals Inc [NASDAQ:EYPT] reported sales of 45.71M for the trailing twelve months, which represents a drop of -30.77%. Gross Profit Margin for this corporation currently stands at 0.91% with Operating Profit Margin at -2.56%, Pretax Profit Margin comes in at -2.26%, and Net Profit Margin reading is -2.27%. To continue investigating profitability, this company’s Return on Assets is posted at -0.34, Equity is -0.43 and Total Capital is -0.46. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.02 points at the first support level, and at 7.31 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.08, and for the 2nd resistance point, it is at 9.44.
Ratios To Look Out For
For context, EyePoint Pharmaceuticals Inc’s Current Ratio is 5.50. Also, the Quick Ratio is 5.45, while the Cash Ratio stands at 1.64. Considering the valuation of this stock, the price to sales ratio is 13.02, the price to book ratio is 2.13.
Transactions by insiders
Recent insider trading involved ANTHONY P. ADAMIS, Director, that happened on Oct 23 ’24 when 67100.0 shares were purchased. Former Director, David R. Guyer completed a deal on Oct 14 ’24 to buy 36975.0 shares. Meanwhile, Director DICICCO WENDY F bought 2567.0 shares on Aug 20 ’24.
